It was the case that the overall survival rate was significantly higher in patients with NPC bearing high levels of RAB22A after chemoradiotherapy compared with those having low levels of RAB22A (Fig. 3n and Supplementary information, Fig. S3g), indicating that higher RAB22A levels predict better prognoses for patients with NPC after chemoradiotherapy. This evidence concerns the gene RAB22A and nasopharyngeal carcinoma.